WW stock forecast, quote, news & analysis

Key Takeaways

• WW International shares declined roughly 17.5% over the last 30 days, falling from about $16.10 to approximately $13.28.
• The pullback reflects sustained pressure on the company's legacy Weight Watchers subscription base and rising competition from GLP-1 weight-loss medications.
• A leadership transition—with Stephen Bye formally assuming the chief executive role in early October—kept investor sentiment cautious.
• Northland Capital Markets initiated coverage with an Outperform rating and a $25 price target in early October, providing a notable counterpoint to the selloff.
• Over the last three months, the stock is down roughly 11%, with an early-autumn rally having fully reversed.

WW International (WW) Company Overview and Market Position

WW International, Inc.—formerly known as Weight Watchers—is a global weight-management and wellness company. Its business is built on subscription-based offerings spanning a digital app, in-person workshops, and a growing clinical-services arm. The company has historically monetized behavioral weight-loss programs, but it has been repositioning toward clinical weight-health services, including facilitating access to GLP-1 medications alongside coaching and community support.

With a market capitalization of roughly $150 million, WW is closely watched as a case study in how an established consumer brand navigates disruption from new obesity treatments. Investors follow the stock for signals on subscriber trends, the growth of its clinical business, and its ability to stabilize revenue after a multi-year decline.

WW International (WW) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, WW shares moved from about $16.10 to approximately $13.28, a decline of about 17.5%. The period was marked by choppy trading: the stock briefly spiked above $17 in late September before steadily giving back those gains through October, closing near $12.75 in the most recent completed session.

The longer three-month trend tells a similar story. From roughly $14.87 in mid-July, WW climbed toward $18 in early September before reversing sharply. As of the latest reading near $13.28, the stock is down about 11% over three months. This places the shares well below their 52-week high of $38.38 and closer to their 52-week low of $8.37.

What Drove WW Stock Price in the Last 30 Days

The 30-day decline was driven primarily by a combination of executive uncertainty and persistent concerns about the core business. Stephen Bye, who was announced as WW's new president and chief executive officer in September, formally commenced the role on October 1, 2026. Leadership transitions of this scale tend to introduce uncertainty around strategy and execution, and WW's investor base responded cautiously as the transition took effect.

At the same time, the structural challenge facing the company has not changed: the rise of GLP-1 weight-loss drugs from manufacturers such as Novo Nordisk (NVO) and Eli Lilly (LLY) continues to pressure demand for traditional behavioral weight-loss programs. Subscriber softness in the legacy behavioral segment remains a central concern.

Not all signals were negative. In early October, Northland Capital Markets initiated coverage with an Outperform rating and a $25 price target, and Millennium Management disclosed a small stake of roughly 0.3% to 0.4% in a mid-October regulatory filing. These developments offered some support but were not enough to offset the broader selling pressure.

What Drove WW Stock Performance Over the Last Quarter

The quarterly narrative was defined by a summer rally that ultimately faded. WW reported second-quarter results in early August that topped consensus estimates, helped by strong cost control and margin performance. That momentum carried the stock toward the $18 level in early September.

The turning point came on September 9, 2026, when shares fell about 17% in a single session following the announcement of the new CEO appointment. Investors signaled skepticism about the leadership change at a pivotal moment for the brand, which is contending with a shrinking behavioral subscriber base, an intensifying competitive threat from obesity medications, and a revenue base that has declined for several consecutive years. The company has reaffirmed full-year 2026 guidance of $620 million to $635 million in revenue, but analyst projections continue to anticipate near-term profitability challenges.

Trending AI Robots

For traders seeking a more systematic approach to volatile names like WW, Tickeron's Trending AI Robots page offers a curated view of its AI-driven trading bots. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, yet only the top-performing and most relevant bots are surfaced in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, giving users the ability to compare approaches before committing capital. Because the selection is refreshed based on recent performance and relevance, it serves as a practical starting point for exploring algorithmic trading. Investors interested in complementing their own research can review the featured bots to see whether any align with their objectives.

WW Stock Forecast Drivers: What Investors Should Watch Next

The next major catalyst is WW's third-quarter earnings report, expected in early November 2026. Investors will focus on end-of-period subscriber counts, the trajectory of the clinical business, adjusted EBITDA, and any updates to full-year guidance. Commentary from the new chief executive on strategy and the company's GLP-1-era initiatives—including its partnership with Google Health to combine wearable technology and AI-powered insights—will also be closely scrutinized.

Beyond earnings, the key themes are the pace of behavioral subscriber declines, the profitability of the clinical segment, and the company's progress in reducing leverage. Macroeconomic conditions and consumer discretionary spending trends may also influence demand. As always, the competitive response from larger weight-loss drug makers remains a defining risk to monitor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations